Minireviews
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Mar 6, 2023; 11(7): 1458-1466
Published online Mar 6, 2023. doi: 10.12998/wjcc.v11.i7.1458
Immune-related adverse events induced by programmed death protein-1 inhibitors from the perspective of lymphoma immunotherapy
Yong-Zhe Hou, Qin Zhang, Hai Bai, Tao Wu, Ya-Jie Chen
Yong-Zhe Hou, Hai Bai, Tao Wu, Department of Hematology, Center of Hematologic Diseases of Chinese PLA, The 940th Hospital of Joint Logistics Support force of Chinese People's Liberation Army, Lanzhou 730050, Gansu Province, China
Yong-Zhe Hou, Qin Zhang, Ya-Jie Chen, Department of First Clinical Medical College, Gansu University of Chinese Medicine, Lanzhou 730030, Gansu Province, China
Yong-Zhe Hou, Key Laboratory of Stem Cells and Gene Drugs of Gansu Province, Lanzhou 730050, Gansu Province, China
Author contributions: Hou YZ and Zhang Q designed and performed the article. Chen YJ, Bai H and Wu T contributed to the critical revision and editing of the article.
Supported by the 2022 Project of Innovation Foundation of Outstanding Graduate Students of Gansu Province; the Graduate Innovation Foundation of Major Project of Education Department of Gansu Province, No. lccx2021001; the Gansu Provincial Science and Technology Plan Project Assignment (Innovation Base and Talent Plan), No. 21JR7RA013; the Gansu Province Innovation Base and Talent Plan (Gansu Province Leukemia Clinical Research Center), No. 21JR7RA015; and the 2022 Hospital Project of The 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, No. 2022yxky015.
Conflict-of-interest statement: All the authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hai Bai, Doctor, Research Scientist, Department of Hematology, Center of Hematologic Diseases of Chinese PLA, The 940th Hospital of Joint Logistics Support force of Chinese People's Liberation Army, No. 333 Nanbinhe Road, Qilihe District, Lanzhou 730050, Gansu Province, China. baihai98@tom.com
Received: November 23, 2022
Peer-review started: November 23, 2022
First decision: January 5, 2023
Revised: January 23, 2023
Accepted: February 13, 2023
Article in press: February 13, 2023
Published online: March 6, 2023
Processing time: 99 Days and 2.6 Hours
Core Tip

Core Tip: Much work on immune checkpoint immunotherapy as cancer therapy has been made in recent years. In lymphoma, the immune checkpoint pathway is used to evade the host immune system and suppress immune cell function. Use of programmed cell death 1 protein (PD-1) inhibitors in lymphoma is supported by their unprecedented clinical efficacy in a range of tumors. Lymphoma patients treated with PD-1 inhibitors inevitably experience immune-related adverse events (irAEs), ranging from mild to life-threatening. Although irAEs can be managed with therapy, severe irAEs may necessitate suspension or even interruption of patient-beneficial PD-1 antibody therapy. It is essential that clinicians take adequate care when irAEs occur.